Grünenthal Enters Agreement with AstraZeneca to Acquire Global Rights to Migraine Treatment Zomig® (Zolmitriptan)

AACHEN, Germany, June 7, 2017 /PRNewswire/ --

- This acquisition further strengthens Gruenenthal's leading position in pain
- With migraine, Gruenenthal adds another major pain indication to its portfolio - a
European market worth EUR 450 million in total

The Gruenenthal Group today announced that it has entered into an agreement with AstraZeneca for the global rights to Zomig(R) (Zolmitriptan) excluding Japan. Zomig(R) is indicated for the acute treatment of migraines and cluster headaches. The transaction is expected to be completed before the end of the second quarter of 2017, subject to regulatory clearances.

"Migraine is a very debilitating disease with more than 75 million people worldwide suffering from attacks that can lead to sensitivity to light or sound, to nausea or even vomiting", explains Gabriel Baertschi, CEO of Gruenenthal. "The acquisition of the well-established Zomig(R) products complements our existing pain portfolio. Migraine has been one of the very few main pain indications we haven't yet been able to offer a solution for. This is an important step to reach our ambition to become a EUR 2 billion company by 2022. It will also support our efforts to bring four to five innovative products to market in the same timeframe."

Mark Mallon, Executive Vice President, Global Product & Portfolio Strategy at AstraZeneca said: "Gruenenthal is an established partner with expertise in the treatment of pain. It is well placed to ensure patients continue to benefit from Zomig(R), and to extend the commercial potential of the medicine through its dedicated salesforce."

Gruenenthal will pay AstraZeneca $ 200 million upon completion. AstraZeneca will also receive up to an additional $ 102 million in future milestone payments. Gruenenthal will acquire the rights to Zomig(R) in all markets outside Japan, including the US, where the rights are licensed to Impax Pharmaceuticals (Impax) who will continue to market Zomig(R) in the US. AstraZeneca will continue to manufacture and supply the medicine to Gruenenthal during a transition period.

About Zomig(R)

Zomig(R) (Zolmitriptan) is indicated for the acute treatment of migraine, and for the acute treatment of cluster headache in the EU. Zomig(R) is available in three formulations: an oral tablet, orally dispersible tablet and nasal spray.

About Gruenenthal

The Gruenenthal Group is an entrepreneurial, science-based pharmaceutical company specialized in pain, gout and inflammation. Our ambition is to deliver four to five new products to patients in diseases with high unmet medical need by 2022 and become a EUR 2 billion company. We are a fully integrated research & development company with a long track record of bringing innovative pain treatments and state-of-the-art technologies to patients. By sustainably investing in our R&D above the industrial average, we are strongly committed to innovation.

Gruenenthal is an independent, family-owned company headquartered in Aachen, Germany. We are present in 32 countries with affiliates in Europe, Latin America and the US. Our products are sold in more than 155 countries and approx. 5,500 employees are working for the Gruenenthal Group worldwide. In 2016, Gruenenthal achieved revenues of approx. EUR 1.4 bn. More information: Follow us on LinkedIn: @GrunenthalGroup [ ]

About AstraZeneca

AstraZeneca is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in three main therapy areas - Oncology, Cardiovascular & Metabolic Diseases and Respiratory. The Company also is selectively active in the areas of Autoimmunity, Neuroscience and Infection. AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. For more information, please visit and follow us on Twitter @AstraZeneca [ ] .

Contact: Steffen Fritzsche, Head of Corporate Communications 
Tel.: +49-241-569-1335, 
Gruenenthal GmbH, 52099 Aachen, Germany, 


PR Newswire

Dit persbericht is via ANP Pers Support naar internationale (vak en online) media gestuurd. Heb je nieuws voor buitenlandse journalisten? Bekijk dan onze mogelijkheden of neem contact met ons op.

Verstuur nu éénmalig een persbericht

Verstuur persberichten en beeldmateriaal naar redacties in binnen- en buitenland. Via het ANP-net, het internationale medianetwerk van PR Newswire of met een perslijst op maat.

Direct persbericht versturen
070 - 41 41 234